Forty-six patients with scleroderma (3 male and 43 female) and 31 healthy controls (6 male and 25 female) were included in the study. Twenty-five patients had limited-type and 21 patients had ...

In a statement, Cabaletta CEO Steven Nichtberger, M.D., highlighted Gavel’s previous experience commercializing cell ...

- 7 of 8 myositis patients achieved clinically meaningful TIS responses after discontinuation of all immunomodulators, while off or actively tapering steroids; responses were sustained throughout the ...

Please provide your email address to receive an email when new articles are posted on . Cancer screening for high-risk patients with scleroderma should involve basic age, sex and risk factor targeted ...

PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell ...